These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 31466808)

  • 1. A personalized approach to the management of VWD.
    Phua CW; Berntorp E
    Transfus Apher Sci; 2019 Oct; 58(5):590-595. PubMed ID: 31466808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
    Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
    Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Von Willebrand factor (Vonvendi®): the first recombinant product licensed for the treatment of von Willebrand disease.
    Franchini M; Mannucci PM
    Expert Rev Hematol; 2016 Sep; 9(9):825-30. PubMed ID: 27427955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Desmopressin (DDAVP) use in patients with von Willebrand disease: A single-centre retrospective review of test response and clinical outcomes.
    Chandrakumaran P; Hews-Girard J; Poon MC
    Haemophilia; 2023 Jul; 29(4):1095-1103. PubMed ID: 37257847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
    Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
    Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management.
    Michiels JJ; van Vliet HH
    Acta Haematol; 2009; 121(2-3):154-66. PubMed ID: 19506362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing treatment of von Willebrand disease by using phenotypic and molecular data.
    Rodeghiero F; Castaman G; Tosetto A
    Hematology Am Soc Hematol Educ Program; 2009; ():113-23. PubMed ID: 20008189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
    Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
    Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance.
    Castaman G; Tosetto A; Federici AB; Rodeghiero F
    Thromb Haemost; 2011 Apr; 105(4):647-54. PubMed ID: 21264446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylaxis escalation in severe von Willebrand disease: a prospective study from the von Willebrand Disease Prophylaxis Network.
    Abshire T; Cox-Gill J; Kempton CL; Leebeek FW; Carcao M; Kouides P; Donfield S; Berntorp E
    J Thromb Haemost; 2015 Sep; 13(9):1585-9. PubMed ID: 25930155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New treatment approaches to von Willebrand disease.
    Lavin M; O'Donnell JS
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):683-689. PubMed ID: 27913547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a rapid von Willebrand factor activity latex immuno assay for monitoring of patients with von Willebrand disease (VWD) receiving DDAVP or VWF replacement therapy.
    Vinayagam S; Simons LR; Chowdary P; Thurlow P; Brooks SV; Riddell AF
    Haemophilia; 2014 Jul; 20(4):e304-10. PubMed ID: 24758424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factor VIII:C increases after desmopressin in a subgroup of patients with autosomal recessive severe von Willebrand disease.
    Castaman G; Lattuada A; Mannucci PM; Rodeghiero F
    Br J Haematol; 1995 Jan; 89(1):147-51. PubMed ID: 7833254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylaxis in von Willebrand disease.
    Franchini M; Targher G; Lippi G
    Ann Hematol; 2007 Oct; 86(10):699-704. PubMed ID: 17634944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of inherited von Willebrand disease in Italy: results from the retrospective study on 1234 patients.
    Federici AB; Bucciarelli P; Castaman G; Baronciani L; Canciani MT; Mazzucconi MG; Morfini M; Rocino A; Schiavoni M; Oliovecchio E; Iorio A; Mannucci PM
    Semin Thromb Hemost; 2011 Jul; 37(5):511-21. PubMed ID: 22102194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effect of Age on von Willebrand Factor and Bleeding Symptoms in von Willebrand Disease.
    Seaman CD; Ragni MV
    Thromb Haemost; 2020 Aug; 120(8):1159-1165. PubMed ID: 32629500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Diagnosis and management of von Willebrand disease].
    Higasa S; Tokugawa T; Sawada A
    Rinsho Ketsueki; 2018; 59(10):2222-2232. PubMed ID: 30305529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring Therapy during Treatment of von Willebrand Disease.
    Favaloro EJ; Pasalic L; Curnow J
    Semin Thromb Hemost; 2017 Apr; 43(3):338-354. PubMed ID: 27472426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.